Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (2): 235-239. doi: 10.19723/j.issn.1671-167X.2021.02.001

    Next Articles

Therapeutic effect of gene silencing peptidyl arginine deaminase 4 on pulmonary interstitial lesions induced by collagen-induced arthritis mice

ZHAO Kai,CHANG Zhi-fang,WANG Zhi-hua,PANG Chun-yan(),WANG Yong-fu()   

  1. Department of Rheumatism and Immunology, the First Affiliated Hospital of Baotou Medical College, Inner Monolia University of Secience and Technology, Inner Mongolia Autoimmunology Key Laboratory, Baotou 014010, Inner Mongolia, China
  • Received:2019-04-22 Online:2021-04-18 Published:2021-04-21
  • Contact: Chun-yan PANG,Yong-fu WANG E-mail:pchy_fighting@163.com;wyf5168@hotmail.com
  • Supported by:
    National Nature Science Foundation of China(81560270)

RICH HTML

  

Abstract:

Objective: To investigate the therapeutic effect of gene silencing peptidyl arginine deaminase 4 (PAD4) on pulmonary interstitial lesions induced by collagen-induced arthritis (CIA) mice, and possible mechanisms. Methods: A CIA mouse model was established in DBA/1 mice, followed by a tail vein injection of the virus solution prepared by the PAD4-siRNA expression vector once a week for 8 times. The mice were sacrificed at the end of the experiment. The expression of PAD4 mRNA in lungs was detected by real-time quantitative PCR (qRT-PCR). The expression of PAD4 protein was detected by tissue immunohistochemistry. Cell culture was performed by spleen tissue. Flow cytometry changes in the ratio of Tfh cells to Tfr cells were examined; lung staining was performed in the lungs to observe changes in lung pathology. Results: (1) Compared with the blank group, the expression of PAD4 mRNA in the lung tissue of the model group increased, the difference was statistically significant (P< 0.05). PAD4 mRNA in the lung tissue of the CIA mice after PAD4-siRNA treatment. The expression level was significantly lower than that of the model group and the negative control group, and the difference was statistically significant (P<0.05). (2) Red fluorescence was less in the lung tissue of the blank group, while more red fluorescence was observed in the inflammatory cell infiltration area and trachea around the lung tissue of the model group and the negative control group, and the red fluorescence of the three groups after PAD4-siRNA treatment was significantly reduced; (3) Compared with the blank group, the proportion of Tfh cells in the model group increased, the difference was statistically significant (P < 0.05), the proportion of Tfh cells in spleen cells of the CIA mice after PAD4-siRNA treatment was significantly lower than that of the model group and the negative control group, the difference was statistically significant (P < 0.05); compared with the blank group, in the mouse spleen cells in the model group the proportion of Tfr cells was slightly decreased, but the difference was not statistically signifi-cant. The proportion of Tfr cells in the spleen cells of the mice increased after PAD4-siRNA treatment, but the difference was statistically significant only in the PAD4-siRNA2 group compared with the model group and the negative control group (P<0.05); (4) The proportion of Tfh/Tfr in the spleen cells of the model group was increased, compared with the blank group, the difference was statistically significant (P<0.05); the ratio of Tfh/Tfr in the three groups after PAD4-siRNA treatment all decreased, the difference was statistically significant (P<0.05); (5) Compared with the blank group, the alveolar wall of the lung tissue of the model group was thickened, the inflammatory cell infiltration was increased, and the lung tissue destruction and inflammatory infiltration of the CIA mice were decreased after PAD4-siRNA treatment. The degree of reduction was reduced. Conclusion: Gene silencing of PAD4 can reduce the proportion of Tfh cells, increase the proportion of Tfr cells, reverse the proportion of Tfh/Tfr, and reduce the degree of interstitial lesions and inflammatory infiltration of lung tissue.

Key words: Rheumatoid arthritis, Peptidyl arginine deaminase 4, Gene silencing, Follicular helper T cells, Follicular regulatory T cell

CLC Number: 

  • R593.22

Figure 1

The PAD4 protein expression in the lungs of CIA mouse A, blank group; B, model group; C, negative control group; D, PAD4-siRNA1 group; E, PAD4-siRNA2 group; F, PAD4-siRNA3 group."

Figure 2

The proportion of Tfh cells in splenocytes of CIA mouse A, blank group; B, model group; C, negative control group; D, PAD4-siRNA1 group; E, PAD4-siRNA2 group; F, PAD4-siRNA3 group.*P<0.05."

Figure 3

The proportion of Tfr cells in splenocytes of CIA mouse A, blank group; B, model group; C, negative control group; D, PAD4-siRNA1 group; E, PAD4-siRNA2 group; F, PAD4-siRNA3 group.*P<0.05."

Figure 4

The changes of Tfh/Tfr cells in splenocytes of CIA mouse A, blank group; B, model group; C, negative control group; D, PAD4-siRNA1 group; E, PAD4-siRNA2 group; F, PAD4-siRNA3 group.*P<0.05."

Figure 5

The pathological changes in the lungs of CIA mouse A, blank group; B, model group; C, negative control group; D, PAD4-siRNA1 group; E, PAD4-siRNA2 group; F, PAD4-siRNA3 group."

[1] Haridas V, Shetty P, Sarathkumar E, et al. Reciprocal regulation of pro-inflammatory Annexin A2 and anti-inflammatory Annexin A1 in the pathogenesis of rheumatoid arthritis[J]. Mol Biol Rep, 2019,46(1):83-95.
doi: 10.1007/s11033-018-4448-5 pmid: 30426384
[2] Yuzhalin AE, Gordon-Weeks AN, Tognoli ML, et al. Colorectal cancer liver metastatic growth depends on PAD4-driver citrullination of the extracellular matrix[J]. Nat Commun, 2018,9(1):4783.
pmid: 30429478
[3] 郭靖, 钱龙, 李向培, 等. 类风湿关节炎患者外周血单个核细胞肽酰基精氨酸脱亚氨酶4表达及组蛋白甲基化水平[J]. 中华内科杂志, 2013,52(11):928-931.
[4] Thanapati S, Ganu M, Giri P, et al. Impaired NK cell functiona-lity and increased TNF-α production as biomarkers of chronic chikungunya arthritis and rheumatoid arthritis[J]. Hum Immunol, 2017,78(4):370-374.
pmid: 28213049
[5] 王建. Th细胞在类风湿关节炎发病作用的研究进展[J]. 临床与病理杂志, 2015,35(2):263-266.
[6] Xu B, Li J, Wu C, et al. CXCL10 and TRAIL are upregulated by TXNDC5 in rheumatoid arthritis fibroblast-like synoviocytes[J]. J Rheumatol, 2018,45(3):335-340.
doi: 10.3899/jrheum.170170 pmid: 29247155
[7] 刘倩, 杨宇, 陈立, 等. 血小板源性生长因子及其受体在类风湿性关节炎大鼠肺组织的表达及与风湿肺关系的探讨[J]. 中国医科大学学报, 2002,31(1):11-14.
[8] Darrah E, Giles JT, Davis RL, et al. Autoantibodies to peptidylarginine deiminase 2 are associated with less severe disease in rheumatoid arthritis[J]. Front Immunol, 2018,9:2696.
doi: 10.3389/fimmu.2018.02696 pmid: 30515171
[9] Apa I, Saliba D, Ponzoni M, et al. TFH-derived dopamine accelelates productive synapses in germinal centres[J]. Nature, 2017,547(7663):318-323.
doi: 10.1038/nature23013 pmid: 28700579
[10] 邹晓月, 熊御云, 张龙锋, 等. 类风湿关节炎患者外周血滤泡辅助性T淋巴细胞百分率的变化及意义[J]. 重庆医学, 2017,46(35):4920-4922.
[11] Wang X, Yang C, Xu F, et al. Imbalance of circulating Tfr/Tfh ratio in patients with rheumatoid arthritis[J]. Clin Exp Med, 2019,19(1):55-64.
[12] Hou S, Clement RL, Diallo A, et al. FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program[J]. J Exp Med, 2019,216(3):605-620.
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[3] Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207.
[4] Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918.
[5] Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925.
[6] Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016.
[7] Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114.
[8] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
[9] Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979.
[10] Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000.
[11] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[12] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[13] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!